BellaSeno

Focus: BellaSeno is a German medical device company specializing in additive manufacturing (3D-printed) implants for reconstructive and aesthetic surgery, currently in Series A stage. The company focuses on polycaprolactone (PCL) scaffold technology for breast and chest wall applications.

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Open Jobs

About BellaSeno

AI assessmentNot Hiring

No open roles listed right now. Follow BellaSeno to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LTFU of PCL Breast Scaffolds Used in 2021-BRV-004

Breast Implant Revision

N/A

Clinical Trials (1)

NCT07383012LTFU of PCL Breast Scaffolds Used in 2021-BRV-004

N/A

Help build intelligence for BellaSeno

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at an early-stage medtech innovator with novel 3D-printing scaffold technology in an underserved surgical reconstruction market
Access to European regulatory pathways (CE mark) and potential US expansion through FDA approval of PCL breast and pectus scaffolds
Lean, focused pipeline addressing high unmet need in breast implant revision and pectus excavatum repair with autologous fat grafting

Watch Out For

Series A stage with undisclosed funding carries significant financial uncertainty and runway risk; no revenue data or employee count provided
Zero active job postings and absence of published research (0 publications on record) suggest minimal hiring momentum and limited scientific validation visibility
Early-stage clinical programs (5 trials, all early phases) with no Phase 2/3 catalysts mean 5+ years to potential commercialization and substantial clinical/regulatory risk

Generated by Claude from BellaSeno's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Implantation of the PCL Breast scaffold with autologous fat grafting

Breast Implant Revision

N/A

Clinical Trials (1)

NCT07367698Scaffold-guided Breast Implant Revision Surgery

N/A

Surgical implantation of the PCL Breast scaffold with autologous fat grafting

Breast Implant Revision

N/A

Clinical Trials (1)

NCT05437757Scaffold-guided Breast Surgery

N/A

PCL Pectus Scaffold implantation and autologous fat grafting

Pectus Excavatum

N/A

Clinical Trials (1)

NCT05451108Pectus Excavatum Camouflage

N/A

PCL Pectus scaffold implantation and autologous fat grafting

Pectus Excavatum

N/A

Clinical Trials (1)

NCT05634070Pectus Excavatum Camouflage (IT)

N/A

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2017

Portfolio: 5 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo